PLEKHS1

Across TCGA pan-cancer cohorts, PLEKHS1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLEKHS1 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLEKHS1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PLEKHS1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and COAD are the cancer types where PLEKHS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.939	0.775	.004	53	view →
UCEC	DFS	Tertile	All	1.000	0.806	.001	18	view →
COAD	DFS	Median	All	0.860	1.000	.049	12	view →
LSCC	DFS	Median	III,IV	0.857	0.397	.004	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLEKHS1–PDAC (OS)

Open the PDAC breakdown →